Company to benefit from Dr. Frankham's strong
commercial and scientific expertise in developing and marketing
biopharmaceutical and natural health products
MONTREAL, Aug. 20, 2019
/CNW/ - Mondias Natural Products Inc. ("Mondias" or the
"Company") (TSXV: NHP) is pleased to announce that the Board of
Directors has appointed Dr. Patrick
Frankham, PhD, MBA, as the Company's new Chief Executive
Officer, effective August 19,
2019.
Dr. Frankham brings more than 25 years of diverse natural
products and pharmaceutical experience across both business and
research leadership roles in domestic and international markets. A
talented product innovator, he is recognized for driving business
results by building products through infrastructure, innovation and
talent.
Prior to joining Mondias, Dr. Frankham was Chief Executive
Officer and a Director of Pivot Pharmaceuticals Inc. since 2014.
During the course of his career, he has also founded several
healthcare start-ups, including healthcare information technology,
services and pharmaceutical companies. His strong scientific
background comes from his professional experience with public and
private companies, including multinational corporations. He has
developed pharmaceutical products in several therapeutic areas and
interacted with global regulatory authorities. Notable
organizations where he held increasing leadership roles include
Boehringer-Ingelheim GmbH, AeternaZentaris, BioAxone Biosciences
and ICON Clinical Research. Dr. Frankham obtained his PhD in
molecular endocrinology from the Université Laval in Canada, and holds an MBA in finance from the
University of Liverpool, in the
United Kingdom.
"I would like to welcome Dr. Frankham as Mondias' new CEO on
behalf of the Board of Directors," said Mr. André Rancourt,
Executive Chairman of Mondias. "We are proud to have attracted such
a high-profile candidate and believe that Dr. Frankham has the
track record to take Mondias to the next stage in its growth plan:
a vast expertise in developing and marketing biopharmaceutical and
natural health products, strong knowledge of the drug regulatory
process, a solid network in both the scientific and the financial
community and broad public company experience. We will also ensure
that he has the tools and resources he needs to make Mondias a
success."
"Mr. Gravel, our outgoing Chief Executive Officer, will stay on
as a consultant to assist Dr. Frankham during a normal transition
period," added Mr. Rancourt. "I wish to thank Mr. Gravel for his
many contributions to Mondias, from taking the Company public to
his involvement in preparing Mondias for future growth."
"I was impressed by Mondias' solid portfolio of natural health
products and its CELEXT07 bio-defense stimulant plant extract,
which has already attracted considerable interest from
multinational corporations in the biopharma and agricultural
sectors," said Dr. Frankham, CEO of Mondias. "My goal in joining
Mondias is to develop the portfolio of innovative products to their
full market potential while raising awareness of the Company among
our stakeholders and potential investors. In the coming weeks, with
the help of the Mondias team, I intend to assess how we can best
develop and market our products to generate top return on
investment for our shareholders."
Mondias has granted an aggregate amount of 700,000 stock options
of the Company to Dr. Frankham as part of his compensation package.
350,000 stock options will vest immediately with the remaining
350,000 stock options vesting on January 1,
2022. The stock options have an exercise price of
$0.13 per share and will expire on
August 19, 2029.
About Mondias Natural Products Inc.
Mondias
specializes in the commercialization and development of
evidence-based botanical products for the healthcare,
bio-agriculture and organic markets. The Company sells both oral
and topical botanical agents to help manage unmet medical needs
through its Holizen Laboratories division. Mondias is also
developing botanical-based specialty fertilizers, biostimulants and
biopesticides for use in the agriculture, horticulture, cannabis
and hops markets, in collaboration with McGill's Faculty of
Agricultural and Environmental Sciences.
For more information, visit: www.mondias.ca
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than statements of historical fact, that address activities,
events or developments that the Company believes, expects or
anticipates will or may occur in the future (including, without
limitation, statements regarding potential acquisitions and
financings) are forward-looking statements. Forward-looking
statements are generally identifiable by the use of the words
"may", "will", "should", "continue", "expect", "anticipate",
"estimate", "believe", "intend", "plan" or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements are subject to a
number of risks and uncertainties, many of which are beyond the
Company's ability to control or predict, that may cause the actual
results of the Company to differ materially from those discussed in
the forward-looking statements. Factors that could cause actual
results or events to differ materially from current expectations
include the Company's inability to obtain sufficient financing to
execute its business plan; competition; regulation; anticipated and
unanticipated costs and delays; the success of the Company's
research and development strategies; the ability to obtain orphan
drug status; the applicability of the discoveries made; the
successful and timely completion and uncertainties related to the
regulatory approval process; the timing of clinical trials; the
timing and outcomes of regulatory or intellectual property
decisions; and other risks disclosed in the Company's public
disclosure record on file with the relevant securities regulatory
authorities. Although the Company has attempted to identify
important factors that could cause actual results or events to
differ materially from those described in forward-looking
statements, there may be other factors that cause results or events
not to be as anticipated, estimated or intended. Readers should not
place undue reliance on forward-looking statements. The
forward-looking statements in this news release are made as of the
date of this news release, and the Company does not undertake any
obligation to publicly update them to reflect new information or
subsequent events or otherwise except as required by applicable
securities legislation.
SOURCE Mondias Natural Products Inc.